Clinical Trial Update: Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating efficacy and safety of iguratimod in steroid-resistant/relapsed immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Iguratimod (iguratimod)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN